Saltar al contenido
Merck

Antimicrobial susceptibility of Ehrlichia phagocytophila.

Antimicrobial agents and chemotherapy (2001-02-22)
H W Horowitz, T C Hsieh, M E Aguero-Rosenfeld, F Kalantarpour, I Chowdhury, G P Wormser, J M Wu
RESUMEN

Human granulocytic ehrlichiosis is a recently described disease caused by an obligate intracellular gram-negative organism recently named Ehrlichia phagocytophila. To expand our knowledge of the susceptibility of E. phagocytophila, we tested six New York State isolates for susceptibility to 12 antimicrobials using an HL-60 cell culture system. All of the isolates were susceptible to doxycycline (MIC, < or =0.125 microg/ml; minimum bactericidal concentration [MBC], 0.125 to 0.5 microg/ml), rifampin (MIC, < or =0.125 microg/ml; MBC, < or =0.125 microg/ml), ofloxacin (MIC, < or =2 microg/ml; MBC, < or =2 microg/ml), levofloxacin (MIC, < or =1 microg/ml; MBC, < or =1 microg/ml), and trovafloxacin (MIC, < or =0.032 microg/ml; MBC, < or =0.032 microg/ml). Isolates were uniformly resistant to amoxicillin, ceftriaxone, erythromycin, azithromycin, clarithromycin, and amikacin. For one strain, the MBC of chloramphenicol was < or =8 microg/ml. These data suggest that quinolone antibiotics and rifampin may be alternative agents for patients with intolerance to tetracyclines.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Amikacin hydrate, aminoglycoside antibiotic